Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Correction

This article was originally published in The Gray Sheet

Executive Summary

An editorial on the need for more long-term drug-eluting stent trials by Joost Daemen and Patrick Serruys, Erasmus Medical Center, Rotterdam, referenced in the Sept. 17 issue of "The Gray Sheet" (1p. 11), was mistakenly cited as appearing in The Lancet; it appears in the Aug. 21 issue of Circulation, a journal of the American Heart Association

You may also be interested in...



Drug-Eluting Stent Research In Brief

Cypher beats Taxus in new meta-analysis: Johnson & Johnson's Cypher sirolimus-eluting coronary stent is associated with lower rates of myocardial infarction than either Boston Scientific's Taxus drug-eluting stent or bare-metal stents, according to a meta-analysis of 38 trials with 18,023 patients published in the Sept. 15 issue of The Lancet. The meta-analysis, led by Christoph Stettler, University of Bern (Switzerland), is a network of head-to-head comparisons combining direct within-trial comparisons between stents and indirect evidence from other trials, matched to maintain randomization. In the analysis, Cypher's hazard ratio for myocardial infarction is 0.81 compared to bare-metal stents and 0.83 compared to Taxus. (A hazard ratio <1.0 indicates less risk.) There was no difference in mortality or overall stent thrombosis between the stents, but the risk of late stent thrombosis (after 30 days) was higher with Taxus (hazard ratio 2.11 compared to bare-metal stents and 1.85 compared to Cypher.) Also, the lower rate of target lesion revascularization seen using drug-eluting stents over bare-metal stents was more pronounced with Cypher than with Taxus, according to Stettler et al

Breckenridge Eyes First Kyprolis Generic With FDA Approval

Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.

Nestlé Sees Importance Of Local Brands In ‘Fragmented’ VMS Market

As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.

UsernamePublicRestriction

Register

MT025329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel